Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. The company offers pharmaceutical products in the areas of anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory, narcotic analgesics, endocrine system, enteral parenteral,… Read more
Xizang Haisco Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd (002653) has an Asset Resilience Ratio of 2.21% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Xizang Haisco Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Xizang Haisco Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥150.13 Million | 2.21% |
| Total Liquid Assets | CN¥150.13 Million | 2.21% |
Asset Resilience Insights
- Limited Liquidity: Xizang Haisco Pharmaceutical Group Co Ltd maintains only 2.21% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xizang Haisco Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Xizang Haisco Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF |
Biotechnology | 25.67% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Exicure Inc
NASDAQ:XCUR |
Biotechnology | 0.00% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Xizang Haisco Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.21% | CN¥150.13 Million | CN¥6.80 Billion | -0.20pp |
| 2023-12-31 | 2.41% | CN¥160.06 Million | CN¥6.65 Billion | +5.77pp |
| 2022-12-31 | -3.36% | CN¥-203.16 Million | CN¥6.05 Billion | +0.30pp |
| 2021-12-31 | -3.66% | CN¥-183.34 Million | CN¥5.01 Billion | -11.07pp |
| 2020-12-31 | 7.41% | CN¥370.32 Million | CN¥5.00 Billion | +7.60pp |
| 2019-12-31 | -0.19% | CN¥-9.32 Million | CN¥5.04 Billion | +0.07pp |
| 2018-12-31 | -0.26% | CN¥-11.29 Million | CN¥4.37 Billion | -0.10pp |
| 2017-12-31 | -0.16% | CN¥-6.64 Million | CN¥4.11 Billion | -0.07pp |
| 2016-12-31 | -0.09% | CN¥-3.22 Million | CN¥3.71 Billion | +0.02pp |
| 2015-12-31 | -0.11% | CN¥-3.45 Million | CN¥3.23 Billion | +0.03pp |
| 2014-12-31 | -0.14% | CN¥-3.89 Million | CN¥2.87 Billion | -0.09pp |
| 2013-12-31 | -0.05% | CN¥-1.14 Million | CN¥2.46 Billion | +0.00pp |
| 2012-12-31 | -0.05% | CN¥-977.11K | CN¥1.95 Billion | -- |
| 2008-12-31 | 0.00% | CN¥0.00 | CN¥353.69 Million | -- |